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a b s t r a c t 
To understand trends in individual responses to medication, one can take a purely data-driven machine 
learning approach, or alternatively apply pharmacokinetics combined with mixed-effects statistical mod- 
elling. To take advantage of the predictive power of machine learning and the explanatory power of 
pharmacokinetics, we propose a latent variable mixture model for learning clusters of pharmacokinetic 
models demonstrated on a clinical data set investigating 11 β-hydroxysteroid dehydrogenase enzymes 
(11 β-HSD) activity in healthy adults. The proposed strategy automatically constructs different population 
models that are not based on prior knowledge or experimental design, but result naturally as mixture 
component models of the global latent variable mixture model. We study the parameter of the underly- 
ing multi-compartment ordinary differential equation model via identiﬁability analysis on the observable 
measurements, which reveals the model is structurally locally identiﬁable. Further approximation with 
a perturbation technique enables eﬃcient training of the proposed probabilistic latent variable mixture 
clustering technique using Estimation Maximization. The training on the clinical data results in 4 clusters 
reﬂecting the prednisone conversion rate over a period of 4 h based on venous blood samples taken at 
20-min intervals. The learned clusters differ in prednisone absorption as well as prednisone/prednisolone 
conversion. In the discussion section we include a detailed investigation of the relationship of the phar- 
macokinetic parameters of the trained cluster models for possible or plausible physiological explanation 
and correlations analysis using additional phenotypic participant measurements. 
© 2018 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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i  1. Introduction 
Glucocorticoids are widely used, with prescriptions for up
to 2.5% of the population for immunomodulatory and anti-
inﬂammatory effects in a number of disease states ( van Staa
et al., 20 0 0 ). Endogenous glucocorticoid hormones (including corti-
sol and cortisone) are a vital part of normal metabolism and phys-
iological function. They are produced by the adrenal cortex under
the regulation of the HPA (hypothalamic-pituitary-adrenal) axis,
in addition to enzymatic action in tissue. Cortisol increases blood∗ Corresponding author at: Faculty of Science and Engineering, University of 
Groningen, P.O. Box 407, Groningen 9700 AK, Netherlands. 
E-mail address: kerstin.bunte@googlemail.com (K. Bunte). 
p  
A  
c
https://doi.org/10.1016/j.jtbi.2018.07.025 
0022-5193/© 2018 The Authors. Published by Elsevier Ltd. This is an open access article uugar, functions as an immune system suppressant, decreases bone
ormation and supports the metabolism of fat, protein and carbo-
ydrates. Unfortunately these hormones are also associated with
dverse features including central obesity, proximal myopathy, os-
eoporosis, hypertension, insulin resistance, psychological effects
nd excessive skin changes, which serve to reﬂect their action in a
ange of metabolically active tissues. These effects regularly affect
atients receiving exogenous glucocorticoid treatment but are par-
icularly demonstrated in the rare condition of endogenous Cush-
ng’s syndrome which can occur as the result of tumours of the
ituitary or adrenal gland or as a result of ectopic secretion of
CTH ( Newell-Price et al., 2006 ) and these are associated with ex-
ess mortality ( Clayton et al., 2016; Hassan-Smith et al., 2012 ). nder the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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s  In recent years initiatives such as Horizon 2020 have been
aunched in order to address the public health challenges of our
geing population. In Europe, those aged > 65 years made up
7 million of the population in 1998, a number projected to rise
o 25 million by 2035 ( Eurostat, 2008; Sakuma and Yamaguchi,
013 ). Healthy life expectancy has not kept up with this increase
n longevity, with a gap between life expectancy and disability
ree life expectancy in the UK of 9 years for women and 7 years
or men at the age of 65 ( Self et al., 2012 ). As a result there has
een much research focus on the role of so-called pre-receptor
etabolism of glucocorticoids via the 11 β-hydroxysteroid dehy-
rogenase enzymes (11 β-HSD), in metabolic conditions (including
besity and diabetes) as well as those associated with adverse
geing (osteoporosis and sarcopenia) which are similar to those
ound in glucocorticoid excess ( Gathercole et al., 2013 ). 
The two isozymes of 11 β-HSD regulate glucocorticoid action
t a tissue level by shuttling them between active and inac-
ive forms. The type 1 enzyme (11 β-HSD1) ampliﬁes local tis-
ue glucocorticoid levels by replacing the C11-keto group with a
11-hydroxyl group, converting endogenous cortisone to cortisol
 Gathercole et al., 2013 ). This activity is also critically important for
xogenously administered synthetic steroids, such as prednisone,
hich is converted by 11 β-HSD1 to its active form (prednisolone).
he type 2 enzyme 11 β-HSD2, on the other hand, catalyzes in vivo
ainly 1 the opposite reaction to 11 β-HSD1, enhancing the inactiva-
ion of cortisol/prednisolone to cortisone/prednisone. The question
s to whether altered metabolism due to more subtle changes re-
ated to ageing or individual genetic differences for example could
esult in changes in glucocorticoid responsive tissues and account
or adverse tissue effects is a compelling one. Assessing the vari-
tion in 11 β-HSD1 activity between individuals, and within indi-
iduals as a result of ageing and lifestyle changes, and the result-
ng morbidity is a signiﬁcant question in the ﬁeld of metabolic re-
earch. 11 β-HSD1 is widely expressed in metabolically active tis-
ues including liver, adipose, muscle, bone, skin and the central
ervous system and the enzyme has been implicated in the patho-
enesis of associated diseases ( Cooper et al., 1993; Tiganescu et al.,
013 ). Cell culture and animal models have suggested that 11 β-
SD1 is a major regulator of obesity and of the features of glu-
ocorticoid excess as seen in Cushing’s Syndrome ( Clayton et al.,
016; Markey et al., 2016; Morgan et al., 2016a; 2016b; 2014 ). Phar-
aceutical companies have developed a number of selective in-
ibitors of 11 β-HSD1 and are assessing their therapeutic potential.
There remains a lack of consensus on the most appropriate
iomarker to measure 11 β-HSD1 activity, which include urine
teroid metabolite ratios after 24 h collections, tissue biopsies to
easure activity and gene expression and dynamic tests such as
he prednisolone generation test. There are limited data on the lat-
er test, which involves administration of oral prednisone and se-
ial blood tests for measurement of prednisone and prednisolone
evels, representative of in vivo activation of this synthetic gluco-
orticoid. This information could inform future study protocols. 
Prednisone has an identical aﬃnity for 11 β-HSD1 as cortisone
nd the interconversion of oral prednisone to prednisolone has
een used as a marker of predominantly hepatic 11 β-HSD1 activ-
ty (reﬂecting ﬁrst pass metabolism) ( Gathercole et al., 2013 ). To
ate only a few studies have used the prednisone generation test
o gain insight into the potential beneﬁts for well-being, healthy
geing and personalized medicine: Tomlinson et al. (2007) in-
estigated the effects of 11 β-HSD1 inhibition in different com-
artments with regard to adipose/fat tissue based on serum cor-
isol and prednisolone generation in 7 healthy male volunteers;
ooper et al. (2002) looked at in vitro (cell culture) activity (as1 11 β-HSD2 is also catalyzing 11 β-HSD1 activation, but less eﬃcient. 
e  
p  
s  pposed to in vivo activity as we investigate in this contribution)
hile Hundertmark et al. (1997) and Chen et al. (1990) looked
t pharmacokinetics in 6 healthy males with IV administration of
rednisolone as opposed to prednisone. 
In vitro biochemical analysis of serum provides a method for as-
essing the activity levels of these enzymes. However it is unclear
ow informative serum activity data are regarding the dynamic
rocesses occurring in vivo . Methods aiming to answer this ques-
ion include in vitro-to-in vivo extrapolation (IVIVE) ( Cho et al.,
014 ) techniques, which have become an important tool for pre-
iction of human effective dosages. However, as pointed out in
ager et al. (2015) , IVIVE in general requires considerably more
xperimental and in silico data than alternative static models. A
ore direct measure of enzymatic activity in vivo is to introduce a
rescribed dose of the pharmacological cortisone analogue, pred-
isone, and to take time series data of the resulting blood concen-
rations, along with the active metabolite prednisolone. This paper
ackles the problem of how to analyse a data set consisting of such
ime series from a group of healthy volunteers. 
A classical pharmacokinetic approach to dealing with such
atasets is to combine multi-compartment ordinary differential
quation model with a mixed effects statistical model of inter-
erson variation ( Beal and Sheiner, 1982; Owen and Fiedler-Kelly,
014 ). The mean (“ﬁxed effect”) and standard deviation (“random
ffect”) associated with the rate constants representing reactions
etween prednisone and prednisolone then provide measures of
entral tendency and variability in 11 β-HSD1/2 activity through
he population under study. For such systems there is often limited
ccess for inputs or perturbations and the mathematical models
hat are generated invariably include state variables with associ-
ted model parameters which are unknown and cannot be directly
easured. These limitations can cause issues when attempting to
nfer or estimate unknown model parameters from sets of obser-
ations and this can severely hinder model validation. It is there-
ore highly desirable to have a formal approach to determine what
dditional inputs and/or measurements are necessary in order to
educe, or remove these limitations and permit the derivation of
odels that can be used for practical purposes with greater con-
dence. Structural identiﬁability arises in the inverse problem of
nferring from the known, or assumed, properties of a system a
uitable model structure and estimates for the corresponding rate
onstants and other parameters. The analysis considers the unique-
ess (or otherwise) of the unknown model parameters from the
nput-output structure corresponding to proposed experiments to
ollect data for parameter estimation (under an assumption of the
vailability of perfect, noise-free observations). This is an impor-
ant, but often overlooked, theoretical prerequisite to experiment
esign, system identiﬁcation and parameter estimation, since esti-
ates for unidentiﬁable parameters are effectively meaningless. If
arameter estimates are to be used to inform about intervention or
nhibition strategies, or other critical decisions, then it is essential
hat the parameters be uniquely identiﬁable. In this paper a struc-
ural identiﬁability analysis of a linear compartmental model de-
eloped to characterise prednisone kinetics is performed using the
aplace transform approach. This analysis demonstrates that from
 structural perspective the model is structurally locally identiﬁ-
ble for the given system observations, thus providing more conﬁ-
ence in the results obtained for subsequent numerical parameter
stimation using actual times series data for these observations. 
A “data driven” approach to analysing such a data set would
e to apply unsupervised clustering methods from the ﬁeld of
achine learning such as k-means ( Bishop, 1995; Lloyd, 1982 ),
elf organizing maps ( Kohonen, 1982 ) and Gaussian mixture mod-
ls ( Feldman and Langberg, 2011 ), in which the data from each
articipant are considered as a vector from a high dimensional
pace. Clustering in the space of observed data either implicitly
224 K. Bunte et al. / Journal of Theoretical Biology 455 (2018) 222–231 
Table 1 
Subject characteristics of the 12 healthy adults recruited from the local population. The last column shows the maximum likelihood cluster membership 
estimate (see Section 3 ). 
ID Age (years) Sex BMI (kg/m 2 ) Total Fat Mass (kg) Total Lean Mass (kg) Fasting Glucose (mmol/L) Cholesterol (mmol/L) Cls 
1 20 Male 25.0 16.1 59.0 5.1 4.2 C2 
2 69 Male 24.0 15.3 45.5 4.5 5.1 C4 
3 26 Male 25.9 17.5 57.7 5.1 4.3 C2 
4 57 Male 27.5 18.5 61.7 5.1 5.8 C1 
5 25 Male 24.1 20.2 46.1 5.5 3.4 C1 
6 54 Male 25.0 16.5 45.0 4.8 5.1 C2 
7 23 Female 22.2 17.2 40.7 4.3 4.3 C3 
8 64 Female 22.0 18.9 39.8 4.9 4.4 C4 
9 24 Female 21.4 18.2 42.6 4.5 5.1 C4 
10 50 Female 24.7 23.3 35.8 4.1 5.7 C2 
11 20 Female 19.9 10.9 36.3 5.0 3.8 C4 
12 60 Female 29.1 33.0 44.8 4.5 6.5 C2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Three-component model schematic. Fast processes ( P  L ) are represented 
with bold arrows. 
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nor explicitly assumes a certain metric or structure of the data.
In this contribution we will pursue a hybrid multidisciplinary
approach of model based clustering integrated with structural
identiﬁability analysis for interpretation of parameter relations and
perturbation theory to reduce the dimensionality of the parame-
ter space. The core of our contribution is based on interpretable
probabilistic inferential models, aiming at grouping individuals in
the space of pharmacokinetic models based on observed data.
Each group/cluster is therefore represented by a prototypical prob-
abilistic model with a speciﬁc pharmacokinetic parameterisation.
This way our proposed strategy automatically constructs differ-
ent “population” models, that are therefore not deﬁned based on
prior knowledge or experimental design, but come out naturally
as mixture component models of the global latent variable mix-
ture model. In contrast to data driven clustering techniques, we
can analyse the parameter relationships and investigate possible
or plausible physiological explanation. The investigation of further
phenotypic measurements of individuals more probable to be rep-
resented by the same cluster model might lead to new hypothesis
of interesting biomarkers for future investigation and clinical stud-
ies. This contribution therefore reveals both the capabilities and
limitations of pharmacokinetic modelling combined with param-
eter estimation and machine learning, demonstrated on a clinical
data set for prednisone conversion as an example of its potential
broader application to modelling of in vivo biochemical systems in
heterogeneous populations. 
2. Materials and methods 
2.1. Clinical data 
The investigations were performed in 12 healthy adults (6 men
and 6 women) recruited from the local population at the Queen
Elizabeth Hospital Birmingham with subject characteristics sum-
marized in Table 1 . Inclusion criteria included body mass index
between 20 to 30 kg/m 2 , females in the follicular phase of their
menstrual cycle, and post-menopausal subjects off estrogen re-
placement therapy. Exclusion criteria included pregnancy, signiﬁ-
cant past medical history (like diabetes mellitus), ischaemic heart
disease, cerebrovascular disease, respiratory disease and epilepsy,
use of drugs including glucocorticoids, beta-blockers, dopamine ag-
onists and anticoagulants. A clinical study in Birmingham was car-
ried out between October 2010 and March 2013. Participants ar-
rived at the NIHR-Wellcome Trust Clinical Research Facility in a
fasted state by 8:30 AM. Baseline blood tests were taken at ap-
proximately 9:00 AM and analysed for urea and electrolytes, lipids,
glucose (Roche Modular System), insulin (colourimatric ELISA from
Mercodia) in addition TSH and free T4 (Advia Centaur; Bayer Di-
agnostics) were sent. 10 mg of prednisone was then adminis-
tered orally with additional venous blood samples taken at 20-in intervals over a period of 4 h with serum extracted and
nalysed for cortisol and cortisone serum concentrations by liq-
id chromatography-mass spectrometry as previously described
 Hassan-Smith et al., 2015 ). Observations including height, weight
nd blood pressure were recorded and body composition was as-
essed using Dual-energy X-ray absorptiometry (DXA) scannning
Hologic Discovery: version Apex 3.0, Hologic Inc). 
thical Approval. The study was approved by the Coventry and
arwickshire Research Ethics Committee (REC reference no.
7/H1211/68) and the Scientiﬁc Committee of the NIHR-Wellcome
rust Clinical Research Facility at the Queen Elizabeth Hospital
irmingham. 
.2. Linear kinetics, three compartment model 
The model ( Fig. 1 ) consists of three compartments, an unob-
erved stomach compartment S in which the prednisone formu-
ation is initially deposited after oral ingestion, a compartment P
epresenting blood concentration (nmol/L) of the inactive metabo-
ite prednisone, and a compartment L representing blood concen-
ration (nmol/L) of the active metabolite prednisolone. Reactions
etween the three compartments are assumed to have linear ki-
etics. This contribution focuses on the in-depth analysis of a lin-
ar kinetic example as a proof of concept, paving the way for anal-
sis with increased complexity, such as non-linear models, in the
uture. Rate constants for the linear kinetics include: k abs for ab-
orption of oral prednisone into the blood, k PL and k LP representing
1 β-HSD1 and 11 β-HSD2 activity converting the inactive metabo-
ite to active form, and vice versa, and excretion constants k Pex and
 Lex quantifying excretion from the blood of prednisone and pred-
isolone respectively. The enzyme activity is assumed to be signif-
cantly faster than either the absorption or excretion respectively,
ustiﬁed by the almost immediate presence in the blood of pred-
isolone observed experimentally. 
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SWith all reactions assumed to have linear kinetics, the mathe-
atical model therefore takes the form: 
dS 
dt 
= −k abs S , 
dP 
dt 
= k abs S − (k Pex + k PL ) P + k LP L , 
dL 
dt 
= k PL P − (k Lex + k LP ) L , 
⎫ ⎪ ⎪ ⎪ ⎪ ⎬ 
⎪ ⎪ ⎪ ⎪ ⎭ 
(1) 
ith initial condition [ S, P, L ]  = [ S 0 , 0 , 0]  at time t = 0 with ob-
ervations: 
 
y 1 
y 2 
y 3 
] 
= 
[ 
0 0 0 
0 1 0 
0 0 1 
] [ 
S 
P 
L 
] 
. (2) 
his model has six parameters, S 0 , k abs , k PL , k LP , k Pex and k Lex and
an be written more compactly in the form: 
dμ
dt 
= A μ, μ(0) = [ S 0 , 0 , 0] T , (3) 
y = Cμ (4) 
here μ(t) = [ S(t ) , P (t ) , L (t )] T , y includes the observable dimen-
ions y 2 and y 3 (corresponding to P and L ) as selected by matrix C
s given in Eq. (2) and the matrix A is deﬁned by: 
 = 
[ −k abs 0 0 
k abs −(k Pex + k PL ) k LP 
0 k PL −(k Lex + k LP ) 
] 
. (5) 
he formulation Eqs. (2) –(5) explicitly deﬁnes model parameter
nd model output structure, which will be analysed in detail in
he following section. 
.3. Structural identiﬁability analysis 
In order to estimate the (unknown) model parameters from the
ata available it is necessary to include in the model output struc-
ure, which corresponds to the function of the model variables that
s to be compared with the data. Before actually collecting exper-
mental data it is necessary to test those model variables with re-
pect to this output structure for uniqueness, since estimates for
nidentiﬁable parameters are meaningless. Such a structural iden-
iﬁability analysis ( Bellman and A˚ström, 1970 ) assesses whether
he observed model output contains enough information to deter-
ine all of the model parameters uniquely ( Jacquez, 1996 ), and
elates only to the structure of the model and output. For linear
ystems there are many well-established techniques for perform-
ng a structural identiﬁability analysis (for further details, and de-
ails of nonlinear approaches, see the tutorial by Godfrey and DiS-
efano III (1987) and other works in the same volume and the book
y Walter, 1982 ). 
Here the uniqueness, of the unknown parameters in a gen-
ral systems model is considered with respect to the outputs. Let
p ∈  ⊂ R r denote a vector comprising the unknown parameters
n the model, which belongs to an open set of admissible vec-
ors ( Evans et al., 2002 ). To make the parameter dependence of the
odel outputs more explicit it is written y ( t , p ). 
Two parameter vectors p , p ∈  are indistinguishable , written
p ∼ p , if they give rise to identical outputs: 
 (t, p) = y (t, p ) for all t ≥ 0 . 
or generic p ∈ , the parameter p i is locally identiﬁable if there is
 neighbourhood, N , of p such that 
p ∈ N , p ∼ p implies that p i = p i . 
n particular, if N =  in the above deﬁnition then p i is globally
dentiﬁable , otherwise it is non-uniquely (locally) identiﬁable . Noticehat, for a given output, a locally identiﬁable parameter can take
ny of a distinct (countable) set of values. If there does not exist a
uitable neighbourhood N then p i is unidentiﬁable and, for a given
utput, can take an (uncountably) inﬁnite set of values. 
A system model is structurally globally identiﬁable (SGI) if all pa-
ameters are globally identiﬁable; it is structurally locally identiﬁ-
ble (SLI) if all parameters are locally identiﬁable and at least one
s non-uniquely identiﬁable; and the model is structurally unidenti-
able (SU) if at least one parameter is unidentiﬁable. 
An established approach to identiﬁability analysis of linear sys-
ems is to take the Laplace transform, reducing the initial value
roblem to an algebraic one. Denoting the Laplace transform of μ
s, 
¯ (s ) = 
∫ ∞ 
0 
e −st μ(t ) dt , (6)
he initial value problem (3) is transformed to, 
μ(0) + s ¯μ(s ) = A ¯μ(s ) , (7)
ence, 
¯ (s ) = (sI − A ) −1 μ(0) . (8)
eﬁning the characteristic polynomial, 
(s ) = det (sI − A ) = (s + k abs ) ·
(s 2 + (k Pex + k PL + k Lex + k LP ) s + k Pex k LP + k Lex k LP + k Pex k Lex ) (9) 
he solution in Laplace space for the observable components is, 
ˆ P (s ) 
ˆ L (s ) 
]
= 
[
ˆ μ2 (s ) 
ˆ μ3 (s ) 
]
= S 0 k abs 
χ(s ) 
[
k LP + k Lex + s 
k PL 
]
. (10) 
xpressing the solution in the form of rational functions yields: 
ˆ 2 (s ) = 1 s + 2 
s 3 + 3 s 2 + 4 s + 5 
(11) 
ˆ 3 (s ) = 6 
s 3 + 3 s 2 + 4 s + 5 
, (12) 
here the coeﬃcients of the powers of s in the numerators and
enominators of Eqs. (11) and (12) are termed the “moment in-
ariants” for these input/output expressions and, in terms of the
riginal model parameters, are given by: 
1 = S 0 k abs , (13) 
2 = S 0 k abs (k LP + k Lex ) , (14) 
3 = k abs + k Pex + k PL + k Lex + k LP , (15) 
4 = k abs (k Pex + k PL + k Lex + k LP ) 
+ k Pex k LP + k Lex k LP + k Pex k Lex , (16 ) 
5 = k abs (k Pex k LP + k Lex k LP + k Pex k Lex ) , (17) 
6 = S 0 k abs k PL . (18) 
he moment invariants for the system are assumed to be measur-
ble (known) through the observations, and are considered unique.
he system is termed (globally/locally) identiﬁable if the mapping 
: [ S 0 , k abs , k PL , k LP , k Pex , k Lex ] 	→ [1 , 2 , 3 , 4 , 5 , 6 ] (19)
s (globally/locally) invertible. Our system Eq. (1) is locally identiﬁ-
ble with three possible solutions as follows from the six moment
nvariants Eqs. (13) –(18) : Eq. (13) implies that the product 
 0 k abs = 1 (20) 
226 K. Bunte et al. / Journal of Theoretical Biology 455 (2018) 222–231 
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Lis structurally globally identiﬁable (SGI). With Eq. (20) substituted in
Eq. (14) it follows that 2 = S 0 k abs (k LP + k Lex ) and: 
2 = 1 (k LP + k Lex ) 
⇒ the sum k LP + k Lex = 2 
1 
(21)
is SGI. This substituted into Eq. (15) 
3 = k abs + k Pex + k PL + (k LP + k Lex ) 
leads to: 
3 = k abs + k Pex + k PL + 
2 
1 
implying the sum 
k abs + k Pex + k PL = 3 −
2 
1 
(22)
is SGI. Furthermore, substituting Eq. (20) in Eq. (18) yields: 
6 = S 0 k abs k PL = 1 k PL 
⇒ k PL = 6 
1 
(23)
is SGI. Note also from Eqs. (23) and (22) that the sum 
k abs + k Pex = 3 −
2 
1 
− 6 
1 
(24)
is SGI. Eq. (17) 
5 
k abs 
= k Pex k LP + k Lex k LP + k Pex k Lex 
substituted into Eq. (16) leads to: 
4 = k abs (k Pex + k PL + k Lex + k LP ) + 
5 
k abs 
and substituting Eqs. (21) and (22) results in: 
4 = k abs 
(
−k abs + 3 −
2 
1 
+ 2 
1 
)
+ 5 
k abs 
, 
which yields a cubic equation in k abs : 
⇒ k 3 abs − 3 k 2 abs + 4 k abs − 5 = 0 . (25)
From analysis using Descartes’ rule of signs it can readily be shown
that Eq. (25) has three changes of signs in the coeﬃcients, which
means it has maximal three positive (real) roots. Since the negative
polynomial f (−k abs ) has no change of sign it has no negative roots.
Furthermore, Eq. (17) can be written as 
5 = k abs (k Pex (k LP + k Lex ) + k Lex k LP ) . (26)
In summary the structural identiﬁability analysis yields: 
1) k abs is structurally locally identiﬁable (SLI) with up to 3 possible
solutions. 
2) S 0 is SLI (based on Eq. (20) ). 
3) k Pex is SLI (follows from Eq. (24) ). 
4) k Lex and k LP are SLI (since k Lex + k LP is SLI seen by Eq. (21) and
k Lex k LP is SLI because of (1), (3), Eqs. (21) and (26) ). 
5) k PL is SGI (see Eq. (23) ). 
2.4. Dimensional analysis 
Because the model is linear, the dependent variables may be
scaled arbitrarily; choosing the initial stomach concentration S 0 
as the scaling factor and denoting dimensionless variables with
primes we have, 
S = S 0 S ′ , P = S 0 P ′ , L = S 0 L ′ . (27)aking as time-scale the inverse of the rate of absorption from the
tomach, i.e. t = k −1 
abs 
t ′ , the problem can be written in terms of di-
ensionless variables as, 
dS ′ 
dt ′ = −S 
′ , 
dP ′ 
dt ′ = S 
′ −
(
ηP + ρ

)
P ′ + 1 

L ′ , 
dL ′ 
dt ′ = 
ρ

P ′ −
(
ηL + 1 

)
L ′ , 
⎫ ⎪ ⎪ ⎪ ⎪ ⎬ 
⎪ ⎪ ⎪ ⎪ ⎭ 
(2 8)
ith initial condition (S ′ , P ′ , L ′ )  = (1 , 0 , 0)  at time t ′ = 0 . The
roups ηP = k Pex /k abs and ηL = k Lex /k abs are the dimensionless ex-
retion rates of prednisone and prednisolone respectively, ρ =
 PL /k LP is the ratio between the rates of forward and backward
onversion between the inactive and active metabolites, and  =
 abs /k LP the ratio between the rate of stomach absorption and rate
f backward conversion from the active to inactive metabolite. The
ssumption that conversion between metabolites occurs on a faster
ime-scale than absorption and excretion implies that  1. 
.5. Quasi-steady approximation 
While model (28) is linear and therefore can be readily solved
ia matrix exponentials, it is possible to exploit the small param-
ter  to yield an even simpler system with two fewer free pa-
ameters. Eq. (28) for S ′ decouples and has the analytic solution
 
′ (t ′ ) = e −t ′ . Substituting for S ′ and adding the remaining equa-
ions yields the following equation for the dynamics of the total
nactive and active metabolites in the blood: 
d(P ′ + L ′ ) 
dt ′ = e 
−t ′ − ηP P ′ − ηL ′ L ′ , (29)
ith initial condition P ′ + L ′ = 0 at t ′ = 0 . 
Eq. (29) is exact. The presence of the small parameter  moti-
ates seeking an approximate solution with a smaller number of
arameters. Examining Eq. (28) and retaining only terms O (1/ )
ields the quasi-steady approximation, 
P ′ ≈ L ′ , (30)
herefore, P ′ + L ′ ≈ (1 + ρ) P ′ ≈ (1 + ρ) ρ−1 L ′ . Intuitively, this rela-
ion can be interpreted as 11 β-HSD1 activity being suﬃciently
apid that the ratio between active and inactive metabolites is ap-
roximately constant over the time-scales associated with absorp-
ion and excretion. Substituting into Eq. (29) we then have the ap-
roximate model for total metabolite dynamics, 
d(P ′ + L ′ ) 
dt ′ ≈ e 
−t ′ −
(
ηP + ρηL 
1 + ρ
)
(P ′ + L ′ ) , (31)
ith initial condition P ′ + L ′ = 0 at t ′ = 0 . The analytic solution is,
(P ′ + L ′ )(t) ≈ 1 + ρ
ηP ′ − 1 + ρ(ηL − 1) 
(
e −t 
′ − exp 
(
−ηP + ρηL 
1 + ρ t 
))
. 
(32)
The dimensionless metabolite concentrations can then be deter-
ined by substituting expression (30) into (32) to give 
 
′ (t ′ ) ≈ 1 
ηP − 1 + ρ(ηL − 1) 
(
e −t 
′ − exp 
(
−ηP + ρηL 
1 + ρ t 
′ 
))
, (33)
 
′ (t ′ ) ≈ ρ
ηP − 1 + ρ(ηL − 1) 
(
e −t 
′ − exp 
(
−ηP + ρηL 
1 + ρ t 
′ 
))
. (34)
he above can be derived formally as the leading order terms
n a perturbation expansion P ′ (t ′ ) = P ′ 0 (t ′ ) + P ′ 1 (t ′ ) + . . . , L ′ (t ′ ) =
 
′ (t ′ ) + L ′ (t ′ ) + . . . 
0 1 
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Fig. 2. Comparison between numerical solution of the full six-parameter model 
(1) and the approximate solution with four parameters given by Eqs. (36) and (37) , 
based on parameter values k abs = 4 , k PL = 90 , k LP = 30 , k Pex = 2 , k Lex = 1 . 6 , S 0 = 10 . 
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L  Following re-dimensionalisation, the approximate solution of
he system Eq. (1) can be expressed in terms of the original vari-
bles and parameters as, 
(t) ≈ S 0 exp (−k abs t) , (35) 
 (t) ≈ S 0 k abs k LP 
k PL k Lex + k LP k Pex − k abs (k PL + k LP ) 
·
(
exp (−k abs t) − exp 
(
−k LP k Pex + k PL k Lex 
k PL + k LP 
t 
))
, (36) 
 (t) ≈ S 0 k abs k PL 
k PL k Lex + k LP k Pex − k abs (k PL + k LP ) 
·
(
exp (−k abs t) − exp 
(
−k LP k Pex + k PL k Lex 
k PL + k LP 
t 
))
. (37) 
The following four-parameter approximate model μ( t ; w ) can
hen be deﬁned for the observed variables P ≈μ2 , L ≈μ3 : 
2 (t;w ) = w 2 ( exp (−w 1 t) − exp ( −w 1 w 3 t ) ) , (38) 
3 (t;w ) = w 2 w 4 ( exp (−w 1 t) − exp ( −w 1 w 3 t ) ) , (39) 
here the parameter vector w = [ w 1 , w 2 , w 3 , w 4 ]  is related to the
hysical parameters by, 
 1 = k abs (40) 
 2 = S 0 k abs k LP 
k PL k Lex + k LP k Pex − k abs (k PL + k LP ) 
(41) 
 3 = k LP k Pex + k PL k Lex 
k abs (k PL + k LP ) 
(42) 
 4 = k PL 
k LP 
. (43) 
n Fig. 2 we see excellent agreement between the numerical solu-
ion of the six-parameter model Eq. (1) computed with the Mat-
ab function ode15s and the four parameters approximate solu-
ion given by Eqs. (36) and (37) , with parameter values k abs = 4 ,
 = 90 , k = 30 , k = 2 , k = 1 . 6 , S = 10 yielding  = 0 . 133 . PL LP Pex Lex 0 .6. Maximum likelihood estimation for clustering of 
harmokokinetic models 
The data for the absorption of prednisone and conversion to
rednisolone (abbreviated by P and L respectively) exhibit large
ariations in healthy individuals. Therefore, the question arises as
o whether there are groups of people with similar trajectories
ver the course of time and if those groups have common phe-
otypical characteristics. 
We assume the generating process for the observed data
an be reasonably well approximated by the simpliﬁed model
qs. (38) and (39) parameterised by w . The aim is to ﬁnd pa-
ameter vectors w k corresponding to different models explaining k
roups of conversion behaviour over the course of time, such that
rednisone ( P ) and prednisolone ( L ) measurements in the serum
f subjects within a cluster are more similar compared to another
luster. We use Maximum Likelihood Estimation of a Gaussian
ixture Model explained in the following. The data set D = { D j } N 
j=1 
s composed of N individuals. For each participant j we assume a
ollection D j = { y j c (t j m ) } o 
j 
c 
m =1 of measurements of P and L at time
oints t 
j 
m . Here y 
j 
c with c ∈ {2, 3} corresponds to noisy measure-
ents of P and L , which are modelled by components μc of the dy-
amical system M approximated by Eqs. (38) and (39) . The number
f available observations of substance c and subject j is denoted by
 
j 
c and may vary across subjects. We assume that the observations
rom substances c are normally distributed with mean component
c and substance related variance σ 2 c . Therefore, the probability of
 measurement y 
j 
c (t 
j 
m ) being produced by component μc (t 
j 
m , w k )
s 
 (y j c (t 
j 
m ) | w k ) = N (y j c (t j m ) ;μc (t j m , w k ) , σ 2 c ) (44) 
ig. 3 illustrates our machine learning model and assumptions
n the data. The curves denote the cluster model concentra-
ions of prednisone μ2 ( t ; w k ) (red) and prednisolone μ3 ( t ; w k )
blue), whereas differently shaped markers represent individual
easurements from participants for both compounds at differ-
nt time points y 
j 
c (t 
j 
m ) respectively. The solid black line illus-
rates the normally distributed observations y 
j 
c=3 (200) centered
t μc=3 (200 , w k ) with variance σ 2 c=3 . Since measurements of dif-
erent individuals are considered independent we write the like-
ihood of the data given parameters 
 = {{ w k , P (k ) } K k =1 , { σc }} as
 (D | 
) = ∏ N j=1 ˜ P (D j | 
) . We maximize the log likelihood: 
og P (D | 
) = 
N ∑ 
j=1 
log ˜ P (D j | 
) (45) 
sing a mixture model 
˜ 
 (D j | 
) = 
K ∑ 
k =1 
P k · ˜ P (D j | 
k ) (46) 
ith priors P k and 
˜ 
 (D j | 
k ) = 
3 ∏ 
c=2 
( 
o j c ∏ 
m =1 
P (y j c (t 
j 
m ) | w k ) 
) 1 /o j c 
. (47) 
e weight each observation to account for the potentially varying
umber of successful measurements o 
j 
c per participant. 
For the EM algorithm we assume that the latent Bernoulli ran-
om indicator variable Z 
j 
k 
is 1 if the data collection D j was gen-
rated from the model parameterised by w k and 0 otherwise. The
omplete log-likelihood is given by 
 ({ Z j 
k 
} , D ) = 
N ∑ 
j=1 
K ∑ 
k =1 
Z j 
k 
log ( ˜  P (D j | 
k ) P k ) . (48)
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Fig. 3. Illustration of the data, variables and assumptions to train our cluster algorithm. P and L represent the compartments for blood concentration of prednisone and 
prednisolone respectively. The markers show example data from subjects with ID 1, 3 and 10 (see Table 1 ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. Median log-likelihood and 50% IQR boxplot versus the number of clusters 
used for the “elbow” method to determine the number of clusters to model the 
data. 
Fig. 5. Complete linkage clustering based on pairwise probabilities P ij of partici- 
pant ID i and ID j appearing together in the same cluster throughout the experiment 
assuming 4 models. 
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ﬁ
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c  The maximum likelihood estimate (MLE) is determined by
marginalizing the likelihood of the observed data by iterating over
2 steps: 
E: Since the complete likelihood is not known we calculate the
expected value of the log likelihood function with respect to
the conditional distribution of Z given D given the current
estimate of the parameters 
( t ) : 
Q(
| 
(t) ) = 
N ∑ 
j=1 
K ∑ 
k =1 
E[ Z j 
k 
] · log ( ˜  P (D j | 
k ) P k ) 
Q(
| 
(t) ) = 
N ∑ 
j=1 
K ∑ 
k =1 
γ (t) 
jk 
· log ( ˜  P (D j | 
k ) P k ) with (49)
γ (t) 
jk 
= 
˜ P (D j | 
(t) 
k 
) P (t) 
k ∑ 
l 
˜ P (D j | 
(t) 
l 
) P (t) 
l 
. (50)
M: Find the parameters maximizing the following quantity: 

(t+1) = arg max 


Q(
| 
(t) ) (51)
3. Results 
We performed experiments varying the number of clusters
from 2 to 6 possible models to represent the time course of pred-
nisone and prednisolone for the respective number of groups of
subjects. For each number of clusters we use leave-one-out cross
validation of the 12 people with 5 independent repetitions result-
ing in 60 clusterings for each experiment. The algorithm is always
initialized with individual ﬁts of randomly chosen training subjects
corresponding to the number of clusters assumed. The resulting
median log-likelihood Eq. (48) and 50% IQR versus the number of
clusters is shown in the boxplot in Fig. 4 . Incrementing the number
of clusters up to 4 increases the performance considerably, after
that adding another cluster does not improve the clustering signif-
icantly. Based on this “elbow criterion” ( Ketchen and Shook, 1996 )
we further analyze 4 class clustering results in detail. 
For the investigation of the models and parameters we ﬁrst
compute the probabilities P ij by counting how often two subjects i
and j appeared together in the same cluster throughout the 60 in-
dependent runs, assuming 4 clusters. We deﬁne 1 − P i j as the pair-
wise distance and perform complete linkage clustering as shown
in the dendrogram Fig. 5 . The cut-off value of 4 clusters is used as
cluster assignment Z 
j 
k 
to initialize our EM procedure once more to
ﬁnd the ﬁnal model parameters for detailed investigation. In this
last experiment we initialize by a least squares individual groupt based on 5 repetitions of random parameters and the resulting
nal models are shown in Fig. 6 . 
. Discussion 
The ﬁnal trained cluster models are very robust with respect to
he random initialization in the training based on the given initial
 cluster assignment of participants extracted from the dendro-
ram Fig. 5 . Therefore, only the average parameters cluster mod-
ls are shown in Fig. 6 . Cluster 1 resembles the slowest absorption
f prednisone and also the least growing concentration of pred-
isolone in the blood. The second slowest absorption rate is cap-
ured by cluster 2. People assigned to that cluster reach higher lev-
ls of prednisolone. People in the fourth cluster reach higher con-
entrations of prednisolone 20 min after administration of pred-
isone and after 100 min it starts to decrease. The third cluster
ontaining only subject ID7 resembles an outlier from the data set.
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Table 2 
Relationship of the original parameters for the 4 cluster models shown in Fig. 6 . We show means and 
standard deviations based on 5 random initializations. 
k Lex = a · k Pex + b
C S 0 · k abs = k PL = a b 
1 3.74362 (0.00976) 5.02783 (0.00614) · k LP −0 . 19889 (0.0 0 024) 0.00480 (0.0 0 0 05) 
2 5.47217 (0.00744) 6.00644 (0.00293) · k LP −0 . 16649 (0.0 0 0 08) 0.00391 (0.0 0 0 05) 
4 21.34430 (0.01347) 7.40155 (0.00212) · k LP −0 . 13511 (0.0 0 0 04) 0.01675 (0.00999) 
3 34.35457 (0.02879) 12.56240 (0.00352) · k LP −0 . 07960 (0.0 0 0 02) 0.01116 (0.0 0 021) 
Fig. 6. Four learned models of prednisone (P; dashed lines) and prednisolone (L; solid lines) blood concentrations and the actual measurements of the 12 subjects ( Table 1 ). 
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Fig. 7. Linear relationship of k Pex and k Lex for clusters C1 − C4 from Fig. 6 . The cir- 
cle mark the point were k Pex = k Lex . 
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t  he conversion pattern of this subject is very different compared
o all other individuals in this data set. 
With the knowledge about the functional relationships of the
arameters from the identiﬁability analysis we can investigate the
rained parameters and investigate possible explanations for the
ehaviour. In order to view the relationship for the original param-
ters ( Fig. 1 ) we solve the linear equation system Eqs. (40) –(43) for
ach of the cluster models. The mean and standard deviation of
hose relationships for each cluster based on the 5 random initial-
zations is shown in Table 2 . Very small standard variations quan-
ify the above statement that the ﬁnal cluster models are very ro-
ust with respect to random initialization. The excretions of pred-
isolone k Lex and prednisone k Pex exhibit a linear antiproportional
elationship: the more prednisone is excreted the lower the rate
or prednisolone. Only a small interval of k Pex values is possibly
ependent on the value of b where k Lex is larger (see Fig. 7 ). The
lusters C 1, C 2, C 4 to C 3 exhibit increasing absorption rate S 0 · k abs 
f prednisone into the blood as can be seen from Table 2 . Pred-
isone is converted to prednisolone by a factor of 5 times faster
han that for cluster 1. For the other clusters this factor is increas-
ng. 
After estimating the ﬁnal cluster assignment we got back to our
edical expert asking for additional information about the par-
icipants to investigate characteristics within the same cluster. Of
ourse, due to the small sample size the following analysis is only
xploratory and we cannot make strong claims, but the investiga-
ion might lead to new hypothesis and provide some evidence for
nteresting measurements for future clinical studies. Therefore, we
ompute the Area Under the Curve (AUC) of prednisolone conver-ion of each cluster model k : 
UC = 
∫ t=240 
t=0 
μ3 (t;w k ) (52) 
nd weight it with the trained mixture component γ jk for each
articipant j resulting in an individual AUC value dependent on
he membership in each cluster. We test the association between
hese AUC values and measurement of the additional clinical satel-
ite data for each individual. First we observe that there are no
trong correlations between the age or BMI in general, with a p -
alue of .45 and .128 respectively. Cortisol on the other hand is
orrelated to the AUC and exhibits a p -value of .006, which is not
ery suprising since prednisolone is a synthetic derivative of cor-
isol processed by the same enzymes as modeled here. Since the
230 K. Bunte et al. / Journal of Theoretical Biology 455 (2018) 222–231 
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 hormonal activity of female and male population is different we
furthermore investigate the correlation dividing the groups by gen-
der. There is some indication that speciﬁc measurements could be
interesting as subject for further investigation, for example we ob-
serve a p -value of .029 for the BMI within men, while it is .47 for
the female participants. The investigation of the phenotypic mea-
surements of individuals that are more probable to be represented
by the same cluster model might therefore lead to new hypothesis
of potentially interesting biomarkers for future investigation and
clinical studies. 
5. Conclusions and future work 
The core of our contribution is based on interpretable prob-
abilistic inferential models aiming at clustering pharmacokinetic
models for the absorption of prednisone in the blood. The collec-
tion of all individual blood measurements is modelled as a proba-
bilistic latent variable model with pharmacokinetic models playing
the role of mixture components. Therefore, each group or cluster
is represented by a prototypical probabilistic model with a speciﬁc
pharmacokinetic parameterisation. This way our proposed strat-
egy automatically constructs different “population” models, that
are therefore not deﬁned based on prior knowledge or experimen-
tal design, but come out naturally as mixture component models
of the global latent variable mixture model. In contrast to solely
data-driven clustering techniques, we can analyse the parameter
relationships and investigate possible or plausible physiological ex-
planation. The strategy is suitable for sparse measurements, which
is especially beneﬁcial if these are collected by an invasive proce-
dure. Our approach is designed for time series measurements po-
tentially taken at different time points and is demonstrated on a
clinical data set investigating the in vivo glucocorticoid activation
by 11 β-HSD1/2 activity in healthy adults. 
The model was thoroughly studied by identiﬁability analysis
and then approximated using the perturbation method. The latent
variable mixture of pharmacokinetic models is trained by an Ex-
pectation Maximization strategy, which is a widely used eﬃcient
natural choice for the estimation of such latent variable models.
We achieved robust results for 4 prototypical cluster models re-
sembling the prednisone/prednisolone concentration in the blood
over the course of 240 min after admission of the drug for the 12
subjects in the data set. We observed a weak correlation of the
AUC of prednisolone concentration in the blood with respect to
the cluster models and the BMI of male suspects, which does not
seem to be immanent for the female participants. The investigation
of further phenotypic measurements of individuals more probable
to be represented by the same cluster model might lead to new
hypothesis of interesting biomarkers for future investigation and
clinical studies. With the availability of more data in the future
the approach can be extended to non-linear pharmacokinetic mod-
els, while this contribution serves as a proof of concept. Our pro-
posal emphasise the potential of exploratory analysis of partially
observed time series data by combining pharmacokinetics, struc-
tural identiﬁability analysis, dimensional analysis/perturbation the-
ory with machine learning. 
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